Christian Denzer1, Friederike Denzer2, Belinda S Lennerz3, Heike Vollbach2, Robert H Lustig4, Martin Wabitsch2. 1. Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, University Medical Center, Ulm, Germany, christian.denzer@uniklinik-ulm.de. 2. Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, University Medical Center, Ulm, Germany. 3. Boston Children's Hospital, Boston, Massachusetts, USA. 4. Division of Endocrinology, Department of Pediatrics, University of California, San Francisco, California, USA.
Abstract
BACKGROUND: A limited number of published case reports suggest a positive effect of dextroamphetamine, an adrenergic agonist affecting both the central nervous system (CNS) and peripheral nervous system, on physical activity and weight in patients with hypothalamic obesity (intractable obesity following CNS insult). Here, we present our clinical experience with dextroamphetamine treatment for hypothalamic obesity. METHODS: The clinical course of all patients started on dextroamphetamine treatment for severe hypothalamic obesity at our institution between 2010 and 2013 is reported. Dextroamphetamine administration was initiated at a single dose of 5 mg per day and titrated to effect up to a dose of 20 mg/day. BMI z-score velocity was calculated as change in BMI z-score over standardized intervals of 12 months. Parameters of treatment success and adverse events were assessed in a standardized fashion. RESULTS: Seven patients (2 males; mean age 17.6 years [range 12.9-24.5]) underwent individual treatment attempts with dextroamphetamine between 2010 and 2013. The primary diagnoses were craniopharyngioma (n = 4), ganglioglioma WHO I (n = 1), astrocytoma (n = 1), and neonatal meningitis (n = 1). Time from initial CNS insult to initiation of dextroamphetamine treatment averaged 5.2 years (range 2.4 months to 16.5 years). All patients demonstrated a steady increase in BMI z-score from the time of initial diagnosis until initiation of dextroamphetamine treatment. Mean baseline BMI z-score was +3.17 ± 0.93 (+1.9 to +4.4). Mean BMI z-score velocity decelerated to -0.18 ± 0.12 per year during the first year of treatment and stabilized at +0.05 ± 0.32 per year during the second year of treatment. No significant adverse events were reported. CONCLUSION: Dextroamphetamine treatment led to stabilization or reduction of BMI z-score in a cohort of 7 patients with hypothalamic obesity, with no adverse effects. Considering the projected increase in BMI z-score according to the natural course of the disease, these findings are promising and warrant further study.
BACKGROUND: A limited number of published case reports suggest a positive effect of dextroamphetamine, an adrenergic agonist affecting both the central nervous system (CNS) and peripheral nervous system, on physical activity and weight in patients with hypothalamic obesity (intractable obesity following CNS insult). Here, we present our clinical experience with dextroamphetamine treatment for hypothalamic obesity. METHODS: The clinical course of all patients started on dextroamphetamine treatment for severe hypothalamic obesity at our institution between 2010 and 2013 is reported. Dextroamphetamine administration was initiated at a single dose of 5 mg per day and titrated to effect up to a dose of 20 mg/day. BMI z-score velocity was calculated as change in BMI z-score over standardized intervals of 12 months. Parameters of treatment success and adverse events were assessed in a standardized fashion. RESULTS: Seven patients (2 males; mean age 17.6 years [range 12.9-24.5]) underwent individual treatment attempts with dextroamphetamine between 2010 and 2013. The primary diagnoses were craniopharyngioma (n = 4), ganglioglioma WHO I (n = 1), astrocytoma (n = 1), and neonatal meningitis (n = 1). Time from initial CNS insult to initiation of dextroamphetamine treatment averaged 5.2 years (range 2.4 months to 16.5 years). All patients demonstrated a steady increase in BMI z-score from the time of initial diagnosis until initiation of dextroamphetamine treatment. Mean baseline BMI z-score was +3.17 ± 0.93 (+1.9 to +4.4). Mean BMI z-score velocity decelerated to -0.18 ± 0.12 per year during the first year of treatment and stabilized at +0.05 ± 0.32 per year during the second year of treatment. No significant adverse events were reported. CONCLUSION:Dextroamphetamine treatment led to stabilization or reduction of BMI z-score in a cohort of 7 patients with hypothalamic obesity, with no adverse effects. Considering the projected increase in BMI z-score according to the natural course of the disease, these findings are promising and warrant further study.
Authors: Christian L Roth; Donald H Hunneman; Ursel Gebhardt; Birgit Stoffel-Wagner; Thomas Reinehr; Hermann L Müller Journal: Pediatr Res Date: 2007-04 Impact factor: 3.756
Authors: A Bereket; W Kiess; R H Lustig; H L Muller; A P Goldstone; R Weiss; Y Yavuz; Z Hochberg Journal: Obes Rev Date: 2012-05-11 Impact factor: 9.213
Authors: Hermann L Müller; Maithé Tauber; Elizabeth A Lawson; Jale Özyurt; Brigitte Bison; Juan-Pedro Martinez-Barbera; Stephanie Puget; Thomas E Merchant; Hanneke M van Santen Journal: Nat Rev Dis Primers Date: 2022-04-21 Impact factor: 52.329
Authors: Meghan Craven; Julia H Crowley; Lucas Chiang; Cassie Kline; Fatema Malbari; Matthew C Hocking; Shana E McCormack Journal: Front Endocrinol (Lausanne) Date: 2022-05-09 Impact factor: 6.055
Authors: Jiska van Schaik; Mila S Welling; Corjan J de Groot; Judith P van Eck; Alicia Juriaans; Marcella Burghard; Sebastianus B J Oude Ophuis; Boudewijn Bakker; Wim J E Tissing; Antoinette Y N Schouten-van Meeteren; Erica L T van den Akker; Hanneke M van Santen Journal: Front Endocrinol (Lausanne) Date: 2022-03-09 Impact factor: 5.555
Authors: Ozair Abawi; Emma C Koster; Mila S Welling; Sanne C M Boeters; Elisabeth F C van Rossum; Mieke M van Haelst; Bibian van der Voorn; Cornelis J de Groot; Erica L T van den Akker Journal: Front Endocrinol (Lausanne) Date: 2022-07-11 Impact factor: 6.055
Authors: J Van Schaik; M Burghard; M H Lequin; E A van Maren; A M van Dijk; T Takken; L B Rehorst-Kleinlugtenbelt; B Bakker; L Meijer; E W Hoving; M Fiocco; A Y N Schouten-van Meeteren; W J E Tissing; H M van Santen Journal: Endocr Connect Date: 2022-07-21 Impact factor: 3.221